EMEA: Risk Management Plans Should Address Vaccine Concerns

Clinical Trials Advisor
Vaccine safety concerns that emerge before marketing should be investigated during preauthorization and addressed in the manufacturer’s risk management plan (RMP), according to a European Medicines Agency (EMEA) draft guideline.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $10.00